Treatment for major depressive disorder (depression) often has partial efficacy and a large portion of patients are treatment resistant. Recent studies implicate reduced somatostatin (SST) interneuron inhibition in depression, and new pharmacology boosting this inhibition via positive allosteric modulators of α5-GABAA receptors (α5-PAM) offers a promising effective treatment. However, testing the effect of α5-PAM on human brain activity is limited, meriting the use of detailed simulations. We utilized our previous detailed computational models of human depression microcircuits with reduced SST interneuron inhibition and α5-PAM effects, to simulate EEG of virtual subjects across depression severity and α5-PAM doses. We developed machine learning models that predicted optimal dose from EEG with high accuracy and recovered microcircuit activity and EEG. This study provides dose prediction models for α5-PAM administration based on EEG biomarkers of depression severity. Given limitations in doing the above in the living human brain, the results and tools we developed will facilitate translation of α5-PAM treatment to clinical use.
Therapeutic dose prediction of α5-GABA receptor modulation from simulated EEG of depression severity
Alexandre Guet-McCreight,F. Mazza,T. Prévot,E. Sibille,Etay Hay
Published 2024 in bioRxiv
ABSTRACT
PUBLICATION RECORD
- Publication year
2024
- Venue
bioRxiv
- Publication date
2024-05-16
- Fields of study
Biology, Medicine, Computer Science
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-82 of 82 references · Page 1 of 1
CITED BY
Showing 1-4 of 4 citing papers · Page 1 of 1